Welcome to our dedicated page for Envoy Medical news (Ticker: COCH), a resource for investors and traders seeking the latest updates and insights on Envoy Medical stock.
Envoy Medical Inc. (NASDAQ: COCH) is a leader in fully implanted hearing solutions, pioneering devices that redefine hearing restoration. This page provides authorized news updates and official press releases directly from the company, offering stakeholders a centralized resource for tracking critical developments.
Investors and healthcare professionals will find timely updates on FDA milestones, clinical trial progress for the Acclaim® Cochlear Implant, and strategic partnerships shaping the future of hearing health. Our curated feed includes product launch announcements, regulatory filings, and analyses of industry trends affecting sensorineural hearing loss treatment.
Key focus areas include advancements in implantable hearing technology, legislative updates impacting device accessibility, and peer-reviewed clinical data. Bookmark this page to stay informed about Envoy Medical's innovations in cochlear implants and middle ear prosthetics, backed by 30+ patents and Breakthrough Device Designations.
Envoy Medical (NASDAQ: COCH) has released its Q4 and full-year 2024 financial results, highlighting significant progress in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant. Six out of planned 10 participants have been enrolled and implanted in the trial's first stage, with two already activated.
Financial results show decreased net revenues due to reduced battery replacement sales from supply chain limitations. R&D expenses increased by $1.2 million year-over-year, primarily due to expanded headcount in engineering and clinical departments. The company ended 2024 with $5.5 million in cash and cash equivalents.
Key developments include successful completion of 24-month follow-up for Early Feasibility Trial patients, selection of seven top-tier cochlear implant programs as trial sites, and progress on the Hearing Device Coverage Clarification Act. New CPT codes for totally implantable active middle ear hearing implants will become effective in July 2025.
Envoy Medical (NASDAQ: COCH) has secured a $10 million financing facility from its largest shareholder, billionaire Glen Taylor, to advance its pivotal clinical trial for the fully implanted Acclaim® cochlear implant. The five-year, unsecured lending facility features deferred interest for the first two years at an 8% rate.
CEO Brent Lucas reported strong enrollment progress in the trial's first stage, with investigational sites noting significant interest in their fully internal cochlear implant design. The funding will support both the clinical trial progression and other operational needs during what the company anticipates to be a transformative year with several important milestones.
Envoy Medical (NASDAQ: COCH), a pioneering hearing health company specializing in fully implanted hearing devices, has announced its participation in the upcoming 37th Annual ROTH Conference. The event will take place from March 16-18, 2025, at the Laguna Cliffs Marriott Resort and Spa in Dana Point, California.
CEO Brent Lucas and CFO David R. Wells will be available for one-on-one meetings with investors and analysts during the conference to discuss recent developments and provide company updates. Interested conference attendees can schedule meetings through a ROTH representative or the conference's online platform.
Envoy Medical (NASDAQ: COCH) has successfully enrolled the first two participants in its pivotal clinical study for the fully implanted Acclaim® cochlear implant. The study aims to evaluate safety and efficacy to support premarket approval (PMA). Both participants were implanted at Ear and Hearing | Center for Neurosciences in Tucson, Arizona by Dr. Abraham Jacob.
The Acclaim® device, which received FDA Breakthrough Device Designation in 2019, functions without external components, potentially offering a significant advantage over traditional cochlear implants. The device was previously implanted in three participants during an early feasibility study at Mayo Clinic in 2022. The current pivotal study involves seven investigational sites total.
According to CEO Brent Lucas, the company has implemented several device modifications based on learnings from the early feasibility study, while maintaining their fundamental design architecture.
Envoy Medical (NASDAQ: COCH) announces significant expansion of its patent portfolio with multiple new patents across different jurisdictions. The company secured two US patents: US Pat. No. 12,214,195 for an Implantable Cochlear System with Inner Ear Sensor (February 4, 2025) and US Pat. No. 12,233,256 for adjustable stereo cochlear implant systems (February 25, 2025).
Additionally, the Japanese Patent Office granted three patents to Envoy in December 2024: JP Pat. No. 7597846 for dual cochlear implant subsystems with common power supply, JP Pat. No. 7598327 for lead characterization in implanted cochlear systems, and JP Pat. No. 7598401 for signal processing from middle ear sensors. The company also received Hong Kong Patent No. HK40097814 on January 3, 2025, covering cochlear implant accessory programming.
Envoy Medical (NASDAQ: COCH) has selected seven investigational sites for its pivotal clinical trial of the Acclaim® cochlear implant, with initial patient enrollment expected in Q1 2025. The FDA-approved IDE study will evaluate this breakthrough device, which is uniquely designed to be fully implanted with no external components, use natural ear anatomy for sound pickup, provide all-day hearing, and feature a multi-day rechargeable battery.
The selected centers include prestigious institutions like Mayo Clinic, Medical University of South Carolina, and Cleveland Clinic Foundation, among others. Each site has a dedicated cochlear implant surgeon and up to two audiologists who will undergo specific product training. The study aims to assess the safety and effectiveness of this potentially game-changing fully implanted cochlear implant.
Envoy Medical (NASDAQ: COCH) has secured four new patents strengthening its position in hearing loss solutions. The company received US Patent No. 12,151,102 on November 25, 2024, and will be granted three European Patents (No. 4255554, 4255555, and 4319866) on January 1, 2025.
The patents cover innovative technologies including: a combination hearing aid and cochlear implant system, cochlear implant stimulation calibration, and electrode impedance diagnostics. These developments focus on improving signal processing, system calibration, and diagnostic capabilities in cochlear implant systems.
Envoy Medical (NASDAQ: COCH) reported Q3 2024 financial results and key developments. The company received FDA approval to begin a pivotal trial for their Acclaim® fully implanted cochlear implant and secured AMA approval for CPT codes for their FDA-approved Esteem® fully implanted middle ear implant. Q3 net revenues were $56,000, down from $80,000 in Q3 2023. R&D expenses increased to $2.8 million from $1.9 million year-over-year. Cash position stood at $4.4 million as of September 30, 2024. The company also received new patents for their Recharge System and Modular Cochlear Implant System.
Envoy Medical announces a peer-reviewed publication in Otology & Neurotology discussing early experiences with their investigational Acclaim® Cochlear Implant. The paper presents initial results from a first-in-human feasibility study involving three patients who are now approaching two years with their implants.
Key findings show that all recipients regularly used their devices, with one patient using it continuously. Two patients reported enhanced benefits by using hearing aids alongside the implant. The device demonstrated 3-5 days of battery life per charge, and its fully implanted nature allows for nighttime use, offering potential security benefits compared to partially implanted devices.
Envoy Medical (NASDAQ: COCH) has been granted European Patent No. 3858425 for its modular cochlear implant system. The patent covers technology for a cochlear implant system capable of receiving input signals from both an implantable source and a wireless receiving device. The system can output stimulation signals based on these inputs using a programmable mixing ratio that determines the relative contributions of each input signal.
